Clinical trials: Seizure
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector
Epilepsy
First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients
The purpose of this study is to examine seizure control and tolerability of Topiramate after either transitioning from previous antiepileptic drug (AED) or adding on to previous AED.
- Trial name
- TEAMS (NCT01627860)
- Testing
- Topiramate add-on therapy, Topiramate monotherapy
- Volunteers
- 55 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Seizure
Acid Suppressing Drug Seizure Epidemiology Study
The purpose of this study is 1. to estimate the incidence of seizure in the general population and stratified by epilepsy status 2.
- Trial name
- NCT01744301
- Testing
- Risk of seizure
- Where
- Spain
- Volunteers
- 8,605 people
- Sponsor
- AstraZeneca
Epilepsy
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
The objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin BID (150 to 600 mg/day titration)…
- Trial name
- LEADER (NCT00288639)
- Testing
- Pregabalin
- Where
- 8 sites in Greece
- Volunteers
- 98 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU
This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity.
- Trial name
- NCT01999777
- Testing
- USL261
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 62 people
- Sponsor
- UCB Biopharma S.P.R.L.
Lennox-Gastaut Syndrome
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.
- Trial name
- NCT01151540
- Testing
- Rufinamide
- Where
- 23 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Eisai Co., Ltd.
Epilepsies, Partial
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
This study will evaluate the effectiveness and safety of seletracetam when it is used in addition to other anti-epileptic medications by patients with partial onset seizures. It will also help to determine the best dose to use.
- Trial name
- NCT00422110
- Testing
- Seletracetam
- Sponsor
- UCB Pharma
Epilepsy, Epilepsy, Focal
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
The purpose of this study is to demonstrate that RWJ-333369 is safe and effective as add-on treatment of partial onset seizures.
- Conditions
- Epilepsy, Epilepsy, Focal, Seizure Disorder, Complex Partial Seizures
- Trial name
- NCT00425282
- Testing
- RWJ-333369
- Volunteers
- 566 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT01091662
- Testing
- Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
- Where
- 62 sites in United States, Bulgaria and 3 more
- Volunteers
- 172 people
- Sponsor
- Sumitomo Pharma America, Inc.
Drug Resistant Partial Onset Seizure
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
- Trial name
- NCT01963208
- Testing
- ganaxolone
- Where
- 71 sites in United States, Australia and 4 more
- Volunteers
- 405 people
- Sponsor
- Marinus Pharmaceuticals
Partial-onset Seizures
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures
- Trial name
- NCT01618695
- Testing
- Perampanel
- Where
- 117 sites in Australia, China and 5 more
- Volunteers
- 940 people
- Sponsor
- Eisai Co., Ltd.
Dravet Syndrome
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS.
- Trial name
- NCT06660394
- Testing
- LP352
- Where
- 105 sites in United States, Australia and 16 more
- Volunteers
- 108 people
- Sponsor
- Longboard Pharmaceuticals
Focal Epilepsy
Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
This is a non-randomized open-label extension study for subjects having completed protocol DA071976 or CLN100P.01.
- Trial name
- NCT04529954
- Testing
- Valproic Acid delivered to ICV
- Where
- 8 sites in Australia, Israel
- Volunteers
- 20 people
- Sponsor
- Cerebral Therapeutics LLC
Diabetic Peripheral Neuropathy, Fibromyalgia
Pharmacokinetics of Two Formulation of Pregabalin
A Randomized, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of Two Formulations of Pregabalin after Oral Administration in Healthy Volunteers under Fasting Conditions
- Conditions
- Diabetic Peripheral Neuropathy, Fibromyalgia, Partial Seizure Disorder
- Trial name
- NCT03712475
- Testing
- Pregabalin
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Presbyopia
Contact Lens Trial Fitting Experience
This study will assess a trial fitting experience with contact lenses.
- Trial name
- NCT07600645
- Testing
- Lens A ( stenfilcon A )
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- CooperVision International Limited (CVIL)
Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
The purpose of this study is to investigate the efficacy and safety of eslicarbazepine acetate (BIA 2-093) as monotherapy for patients with newly diagnosed partial-onset seizures.
- Trial name
- NCT01162460
- Testing
- Eslicarbazepine acetate (BIA 2-093)
- Where
- Portugal
- Volunteers
- 815 people
- Sponsor
- Bial - Portela C S.A.
Epilepsies, Partial
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures
- Trial name
- NCT06590896
- Testing
- Cenobamate
- Where
- 29 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Partial Onset Seizures
Phase II BGG492 Capsule Extension for Partial Epilepsy
This long-term extension study will assess the safety, tolerability and efficacy of BGG492 as adjunctive treatment in patients with partial onset seizures.
- Trial name
- NCT01338805
- Testing
- BGG492
- Where
- 16 sites in United States, Germany and 4 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Hearing Loss
Tuned App Self-Fitting vs. Professional Fitting
The aim of the study is to compare the perceived outcome of the self-fitting performed by the participants using the Tuned mobile application with the traditional professional fitting as performed by a licensed professional…
- Trial name
- NCT05869266
- Testing
- professional fitting vs. self fitting
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Tuned Ltd.